Direct NMR Probing of Hydration Shells of Protein Ligand Interfaces and Its Application to Drug Design-Reference-Cited by-同舟云学术

Direct NMR Probing of Hydration Shells of Protein Ligand Interfaces and Its Application to Drug Design

Published:2017-10-01 Issue:21 Volume:60 Page:8708-8715
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Geist Leonhard¹^ORCID,Mayer Moriz²,Cockcroft Xiao-Ling²,Wolkerstorfer Bernhard²,Kessler Dirk²,Engelhardt Harald²,McConnell Darryl B.²,Konrat Robert¹

Affiliation:

1. Christian Doppler Laboratory for High-Content Structural Biology and Biotechnology, Department of Structural and Computational Biology, University of Vienna, Campus Vienna Biocenter 5, A-1030 Vienna, Austria

2. Boehringer Ingelheim RCV GmbH & Co. KG, Dr.-Boehringer-Gasse 5-11, A-1121 Vienna, Austria

Funder

Christian Doppler Forschungsgesellschaft

Boehringer Ingelheim

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00845

Reference31 articles.

1. Group Epitope Mapping by Saturation Transfer Difference NMR To Identify Segments of a Ligand in Direct Contact with a Protein Receptor

2. Evaluation of Solvent Accessibility Epitopes for Different Dehydrogenase Inhibitors

3. Fluorine-NMR Experiments for High-Throughput Screening: Theoretical Aspects, Practical Considerations, and Range of Applicability

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fast Quantitative Validation of 3D Models of Low-Affinity Protein–Ligand Complexes by STD NMR Spectroscopy;Journal of Medicinal Chemistry;2024-06-07

2. Affinity measurement of strong ligands with NMR spectroscopy: Limitations and ways to overcome them;Progress in Nuclear Magnetic Resonance Spectroscopy;2023-11

3. Investigating the hidden mechanism underlying the tau interaction by methylene blue;2023-05-30

4. Roles of interfacial water states on advanced biomedical material design;Advanced Drug Delivery Reviews;2022-07

5. Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target;Journal of Medicinal Chemistry;2021-12-27